# Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

> **NCT02482753** · PHASE3 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 365 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Chidamide
- **DRUG:** exemestane
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02482753
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-03
- **Final completion:** 2021-02
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482753, "Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02482753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*